Descripción de la empresa
Scinai Immunotherapeutics Ltd. operates as a biopharmaceutical entity dedicated to the development, manufacturing, and commercialization of biological products specifically designed to address inflammation and immunology for the treatment of infectious and autoimmune diseases within Israel. The company utilizes a specialized technology platform that focuses on creating nanosized VHH antibodies, commonly referred to as nanoAbs, which are engineered to target specific disease mechanisms. This firm functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage advancements in immunology for therapeutic applications. With a market capitalization of $2.02M and annual revenue of $1.31M, the company represents a micro-cap enterprise with a minimal operational footprint, indicated by the absence of available employee data. The valuation metrics suggest that the company is in a nascent stage of its commercial lifecycle, where limited revenue generation and a small market cap reflect the high-risk, high-potential nature typical of early-stage biotechnology firms focusing on novel antibody technologies.
Salud financiera
Scinai Immunotherapeutics reported a total revenue of $1.31M over the trailing twelve months, yet it posted a net income of $-8,307,000 and an EBITDA of $-6,121,000, revealing a significant structural gap between top-line sales and profitability. This substantial divergence between revenue and net income indicates that the company's cost structure is heavily weighted toward research and development expenses, which are typical for biotechs in the clinical trial or pre-revenue phases. The company's free cash flow stands at $-3,408,750, signaling that the business is currently burning cash to fund its operations and technological development rather than generating liquidity from its current activities. When analyzing profitability efficiency, the gross margin is reported at -202.3%, the operating margin at -702.4%, and the profit margin at 0.0%, all of which reflect the intense cost pressures associated with scaling biological product manufacturing before achieving commercial volume. On the balance sheet, the company holds $1.66M in cash against $2.27M in debt, resulting in a debt-to-equity ratio of 27.98, which characterizes the firm as leveraged relative to its equity base. Despite the debt load, the current ratio of 1.30 suggests that the company maintains sufficient short-term liquid assets to cover its immediate liabilities without immediate distress. Furthermore, the return on equity is -91.9% and the return on assets is -37.6%, metrics that reveal that management has not yet achieved positive capital efficiency and that equity and asset bases are currently being depleted rather than generating returns.
Evaluación de valoración
The trailing twelve-month P/E ratio and forward P/E ratio are both listed as N/A due to the company's lack of positive earnings, which prevents the calculation of traditional earnings-based valuation multiples. The absence of a forward P/E implies that the market is not currently pricing in a near-term earnings trajectory that would allow for a standard earnings multiple comparison. Instead, the market values the company based on its price-to-book ratio of 0.39, which indicates that the stock trades at a significant discount to its tangible book value. Additionally, the price-to-sales ratio of 1.54 and the EV/EBITDA of -1294.02 provide alternative valuation perspectives, suggesting that investors are pricing the company based on revenue potential rather than profitability or enterprise value relative to earnings. The stock has demonstrated significant price volatility over the last year, trading between a 52-week low of $0.55 and a 52-week high of $6.18. Based on the 52-week range provided, the current trading price sits within a wide band of uncertainty, reflecting the speculative nature of the investment. The beta value is listed as N/A, meaning that the stock's volatility relative to the broader market index cannot be quantified using standard historical correlation data available in this dataset.
Growth & Income
Scinai Immunotherapeutics has demonstrated a revenue growth rate of 30.6% year-over-year, while earnings growth is listed as N/A due to the persistent net losses reported in the trailing twelve months. The disparity between positive revenue growth and the absence of earnings growth highlights that top-line expansion is outpacing the ability of the company to convert sales into net profit, a common dynamic in the early development stages of biotechnology. Regarding income distribution, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute dividends to shareholders. This non-dividend profile is consistent with the company's strategy of reinvesting all available capital, including its $1.66M cash reserves, back into research and development to advance its nanosized VHH antibody pipeline. The overall growth and income profile of Scinai Immunotherapeutics is characterized by strong revenue expansion coupled with a complete absence of cash returns to investors, relying entirely on future clinical success and commercialization to drive value creation.